Morrow, Matthew P, Gillespie, Elisabeth, Sylvester, Albert, Amin, Milan R, Belafsky, Peter C, Best, Simon R, Friedman, Aaron D, Klein, Adam M, Lott, David G, Mau, Ted, Paniello, Randal C, Pransky, Seth M, Saba, Nabil F, Tan, Grace S, Wisotsky, Sadie, Marcus, Sarah A, Reuschel, Emma L, Reed, Katherine S, Weiner, David B, Dallas, Michael, and Skolnik, Jeffrey M. DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Retrieved from https://par.nsf.gov/biblio/10609512. Nature Communications 16.1 Web. doi:10.1038/s41467-025-56729-6.

Morrow, Matthew P, Gillespie, Elisabeth, Sylvester, Albert, Amin, Milan R, Belafsky, Peter C, Best, Simon R, Friedman, Aaron D, Klein, Adam M, Lott, David G, Mau, Ted, Paniello, Randal C, Pransky, Seth M, Saba, Nabil F, Tan, Grace S, Wisotsky, Sadie, Marcus, Sarah A, Reuschel, Emma L, Reed, Katherine S, Weiner, David B, Dallas, Michael, & Skolnik, Jeffrey M. DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Nature Communications, 16 (1). Retrieved from https://par.nsf.gov/biblio/10609512. https://doi.org/10.1038/s41467-025-56729-6

Morrow, Matthew P, Gillespie, Elisabeth, Sylvester, Albert, Amin, Milan R, Belafsky, Peter C, Best, Simon R, Friedman, Aaron D, Klein, Adam M, Lott, David G, Mau, Ted, Paniello, Randal C, Pransky, Seth M, Saba, Nabil F, Tan, Grace S, Wisotsky, Sadie, Marcus, Sarah A, Reuschel, Emma L, Reed, Katherine S, Weiner, David B, Dallas, Michael, and Skolnik, Jeffrey M. "DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107". Nature Communications 16 (1). Country unknown/Code not available: Nature. https://doi.org/10.1038/s41467-025-56729-6. https://par.nsf.gov/biblio/10609512.

@article{osti_10609512,
place = {Country unknown/Code not available}, title = {DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107}, url = {https://par.nsf.gov/biblio/10609512}, DOI = {10.1038/s41467-025-56729-6}, abstractNote = {}, journal = {Nature Communications}, volume = {16}, number = {1}, publisher = {Nature}, author = {Morrow, Matthew P and Gillespie, Elisabeth and Sylvester, Albert and Amin, Milan R and Belafsky, Peter C and Best, Simon R and Friedman, Aaron D and Klein, Adam M and Lott, David G and Mau, Ted and Paniello, Randal C and Pransky, Seth M and Saba, Nabil F and Tan, Grace S and Wisotsky, Sadie and Marcus, Sarah A and Reuschel, Emma L and Reed, Katherine S and Weiner, David B and Dallas, Michael and Skolnik, Jeffrey M}, }